ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.Journal for immunotherapy of cancer · 2023Trial
- Article
- Identification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy.Discover oncology · 2026Article
- Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database.Cancer science · 2026Article
- Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma.Scientific reports · 2026Article
- Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment.AAPS PharmSciTech · 2026Article
- Pleural Mesothelioma: Current Therapeutic Strategies and Future Directions.Current oncology reports · 2026Review
- Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.Molecular therapy. Oncology · 2025Article
- Trends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.Cancer medicine · 2025Article
- Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review.Translational lung cancer research · 2025Review
- Narciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models.International journal of molecular sciences · 2025Article
- Multi-omics integration reveals CYTL1 and H6PD as key regulators of tumor metabolism in mesothelioma.Genes & genomics · 2025Article
- Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition repressesLife science alliance · 2025Article
- Inclusion of anti-vascular therapy as a promising option for later-line treatment of malignant pleural mesothelioma: a retrospective study.Journal of thoracic disease · 2025Article
- Gelatinous pleural effusion in advanced lung adenocarcinoma: a case report.Journal of medical case reports · 2025Article
- A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.Journal of clinical medicine · 2025Article
- PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy.Non-coding RNA research · 2025Article
- Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.JTO clinical and research reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.